TTX-030 is a monoclonal antibody that inhibits the activity of
Tizona Therapeutics is leading the development of TTX-030 through the completion of Phase 1b studies, after which AbbVie has an exclusive option to lead global development and commercial activities. Tizona retains an option to co-develop and co-promote TTX-030 in the U.S.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted, Approved)|
|Lymphoma (in combination with pembrolizumab)||n/a||